<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591785</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 11-0038</org_study_id>
    <nct_id>NCT01591785</nct_id>
  </id_info>
  <brief_title>Treatment of Staphylococcus Aureus Colonization in Hand Eczema</brief_title>
  <official_title>An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Goldenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a chronic disease characterized by itching and eczematous lesions. In&#xD;
      adults, eczema commonly localizes to the hands or feet. Several studies have implicated&#xD;
      bacterial contamination, especially with Staphylococcus aureus (S. aureus), to be a factor in&#xD;
      atopic dermatitis, as infection with this bacteria correlates with disease severity. No trial&#xD;
      to date has investigated how to treat S. aureus infection in adults with hand or hand/foot&#xD;
      dermatitis. Using retapamulin ointment in the nose and on the hands or hands/feet, the&#xD;
      investigators expect to have a significant clearance rate of s. aureus infection. The&#xD;
      investigators believe that treating the bacterial infection along with treating the condition&#xD;
      with a topical corticosteroid will significantly decrease the severity of hand/foot&#xD;
      dermatitis in our study population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Study Objectives:&#xD;
&#xD;
        1. To evaluate the efficacy of retapamulin 1% ointment with clobetasol propionate 0.05%&#xD;
           foam versus vehicle ointment with clobetasol propionate 0.05% foam as a treatment&#xD;
           regimen for hand or hand/foot atopic dermatitis.&#xD;
&#xD;
        2. To evaluate the incidence of intranasal and hand/foot S aureus carriage rates in&#xD;
           subjects with hand/foot atopic dermatitis via cultures of an anterior nare and the most&#xD;
           severely graded target lesion of the hand/foot dermatitis.&#xD;
&#xD;
        3. To evaluate the incidence of mupirocin-resistance and methicillin-resistance in S aureus&#xD;
           isolates in subjects with hand/foot atopic dermatitis via cultures of an anterior nare&#xD;
           and the most severely graded target lesion of the hand/foot dermatitis.&#xD;
&#xD;
      Primary and secondary endpoints will be analyzed by appropriate statistical models by a&#xD;
      qualified statistician. Any results of this pilot study will be treated as exploratory and&#xD;
      hypothesis generating.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With PGA of 0 or 1</measure>
    <time_frame>Day 15</time_frame>
    <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With PGA of 0 or 1</measure>
    <time_frame>Day 28</time_frame>
    <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Staph Aureus Culture Results</measure>
    <time_frame>Day 15</time_frame>
    <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 15 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staph Aureus Culture Results</measure>
    <time_frame>Day 28</time_frame>
    <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 28 compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hand Eczema</condition>
  <condition>Foot Eczema</condition>
  <arm_group>
    <arm_group_label>Retapamulin 1% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ointment for 5 days AND clobetasol propionate foam for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retapamulin 1% ointment</intervention_name>
    <description>Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days</description>
    <arm_group_label>Retapamulin 1% ointment</arm_group_label>
    <other_name>Altabax and Olux Foam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ointment for 5 days AND clobetasol propionate foam for 14 days</description>
    <arm_group_label>Placebo ointment</arm_group_label>
    <other_name>Petroleum jelly</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects at least 18 years of age with a clear diagnosis of&#xD;
             moderate-to-severe hand or hand/foot dermatitis.&#xD;
&#xD;
          -  Subjects must be in general good health as confirmed by a medical history.&#xD;
&#xD;
          -  Subjects must be capable of understanding and willing to provide a signed and dated&#xD;
             written voluntary informed consent before any protocol specific procedures are&#xD;
             performed.&#xD;
&#xD;
          -  At the Baseline Visit, Subjects must have a Physician's Global Assessment (PGA) of at&#xD;
             least 3 (moderate severity).&#xD;
&#xD;
          -  Subject must be willing and able to participate in the study as an outpatient, making&#xD;
             frequent visits to the study center during the treatment and follow-up period periods&#xD;
             and comply with all study requirements.&#xD;
&#xD;
          -  If a subject is a female of childbearing potential she must have a negative urine&#xD;
             pregnancy test prior to study treatment initiation and must agree to use an approved&#xD;
             method of birth control during the study period (barrier, oral, injection,&#xD;
             intrauterine). NOTE: Post-menopausal (amenorrhea for at least one year) or surgically&#xD;
             sterile (tubal ligation and/or hysterectomy) females are categorized as&#xD;
             non-childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking subjects&#xD;
&#xD;
          -  Females who are pregnant, breast feeding, or attempting to conceive.&#xD;
&#xD;
          -  Subjects with a history of known or suspected intolerance to any of the excipients of&#xD;
             retapamulin 1% ointment or clobetasol propionate 0.05% foam.&#xD;
&#xD;
          -  Subjects who have used any topical corticosteroids, topical antibiotics, topical&#xD;
             immunosuppressants, other topical therapies (tar, calcineurin inhibitors), or&#xD;
             phototherapy (PUVA, UVB) within eight weeks of the Baseline Visit.&#xD;
&#xD;
          -  Subjects who have used any systemic corticosteroids, systemic antibiotics, or systemic&#xD;
             immunosuppressants therapies within eight weeks of the Baseline Visit.&#xD;
&#xD;
          -  Subjects with any overt signs of skin atrophy, telangiectasias, and/or striae in the&#xD;
             target area(s).&#xD;
&#xD;
          -  Subjects with any active skin malignancy.&#xD;
&#xD;
          -  Subjects requiring the use of medications known to alter the course of atopic&#xD;
             dermatitis during the study period.&#xD;
&#xD;
          -  Subjects who are currently participating in or, within the previous 28 days, have&#xD;
             participated in another study for the treatment for atopic dermatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Goldenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meding B, Lantto R, Lindahl G, Wrangsjö K, Bengtsson B. Occupational skin disease in Sweden--a 12-year follow-up. Contact Dermatitis. 2005 Dec;53(6):308-13.</citation>
    <PMID>16364116</PMID>
  </reference>
  <reference>
    <citation>Williams RE, Gibson AG, Aitchison TC, Lever R, Mackie RM. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol. 1990 Oct;123(4):493-501.</citation>
    <PMID>2095181</PMID>
  </reference>
  <reference>
    <citation>Hanifin JM, Rogge JL. Staphylococcal infections in patients with atopic dermatitis. Arch Dermatol. 1977 Oct;113(10):1383-6.</citation>
    <PMID>911165</PMID>
  </reference>
  <reference>
    <citation>Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974 May;90(5):525-30.</citation>
    <PMID>4601016</PMID>
  </reference>
  <reference>
    <citation>Jensen JM, Fölster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, Schütze S, Proksch E. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol. 2004 Jun;122(6):1423-31.</citation>
    <PMID>15175033</PMID>
  </reference>
  <reference>
    <citation>Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol. 2002 Aug;119(2):433-9.</citation>
    <PMID>12190867</PMID>
  </reference>
  <reference>
    <citation>Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, Takehara K, Diamandis EP. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol. 2007 Jun;16(6):513-9.</citation>
    <PMID>17518992</PMID>
  </reference>
  <reference>
    <citation>Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, Carrick T, Evans AT, Liao H, Zhao Y, Campbell LE, Schmuth M, Gruber R, Janecke AR, Elias PM, van Steensel MA, Nagtzaam I, van Geel M, Steijlen PM, Munro CS, Bradley DG, Palmer CN, Smith FJ, McLean WH, Irvine AD. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007 May;39(5):650-4. Epub 2007 Apr 8.</citation>
    <PMID>17417636</PMID>
  </reference>
  <reference>
    <citation>Haslund P, Bangsgaard N, Jarløv JO, Skov L, Skov R, Agner T. Staphylococcus aureus and hand eczema severity. Br J Dermatol. 2009 Oct;161(4):772-7. doi: 10.1111/j.1365-2133.2009.09353.x. Epub 2009 Jul 3.</citation>
    <PMID>19575755</PMID>
  </reference>
  <reference>
    <citation>Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May;123(5):e808-14. doi: 10.1542/peds.2008-2217.</citation>
    <PMID>19403473</PMID>
  </reference>
  <reference>
    <citation>Naderer OJ, A.M., Roberts K, et al. , Nasal Decolonization of persistent Staphylococcus aureus carriers with twice daily application of retapamulin ointment, 1%, for 3 or 5 days. , in Presented at the joint 48th annual interscience conference on antimicrobial agents adn chemotherapy at the 46th Annual Meeting of Infectious Diseases Society of America. 2008: Washington DC.</citation>
  </reference>
  <results_reference>
    <citation>Haddican M, Linkner RV, Singer G, Jim SC, Gagliotti M, Goldenberg G. Retapamulin 1% Ointment and Clobetasol Propionate 0.05% Foam is More Efficacious than Vehicle Ointment and Clobetasol 0.05% Propionate Foam in the Treatment of Hand/Foot Dermatitis: A Single Center, Randomized, Double-blind Study. J Clin Aesthet Dermatol. 2014 Jul;7(7):32-6.</citation>
    <PMID>25053981</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Gary Goldenberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hand</keyword>
  <keyword>Foot</keyword>
  <keyword>Eczema</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retapamulin</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from January 2012 to August 2012, all subjects were enrolled at one site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Retapamulin 1% Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>worsening condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Retapamulin 1% Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" lower_limit="22" upper_limit="77"/>
                    <measurement group_id="B2" value="44.4" lower_limit="23" upper_limit="70"/>
                    <measurement group_id="B3" value="43" lower_limit="22" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment (PGA)</title>
          <description>0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
= Almost clear (just perceptible erythema and papulation/infiltration)&#xD;
= Mild (mild erythema and papulation/infiltration)&#xD;
= Moderate (moderate erythema and papulation/infiltration, +/- lichenification, +/- excoriation)&#xD;
= Severe (severe erythema and papulation infiltration, + lichenification/excoriation, +/- oozing/weeping)&#xD;
= Very severe (very severe erythema and papulation/infiltration, + lichenification, + excoriation, +oozing/weeping)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B2" value="3.7" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B3" value="3.6" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With PGA of 0 or 1</title>
        <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retapamulin 1% Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PGA of 0 or 1</title>
          <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With PGA of 0 or 1</title>
        <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retapamulin 1% Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PGA of 0 or 1</title>
          <description>Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis)&#xD;
1 = Almost clear (just perceptible erythema and papulation/infiltration)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Staph Aureus Culture Results</title>
        <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 15 compared to baseline</description>
        <time_frame>Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retapamulin 1% Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Staph Aureus Culture Results</title>
          <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 15 compared to baseline</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0495</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Staph Aureus Culture Results</title>
        <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 28 compared to baseline</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retapamulin 1% Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Staph Aureus Culture Results</title>
          <description>The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 28 compared to baseline</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Retapamulin 1% Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and Retapamulin 1% ointment for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Ointment</title>
          <description>twice daily topical application of clobetasol propionate foam 0.05% for 14 days and placebo ointment for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema flare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study size was small. Study was only four weeks in duration, which is a snap-shot of a chronic life-long disease. Study was a single-center study which might not be a representative of the general population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gary Goldenberg, MD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6500</phone>
      <email>garygoldenbergmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

